Exelixis Employs Novel Adaptive Trial Design To Evaluate Cabozantinib In Multiple Cancers
This article was originally published in Pharmaceutical Approvals Monthly
Exelixis Inc.'s investigational cancer drug cabozantinib demonstrated activity in patients with nine kinds of cancer as part of a single Phase II trial that employs a novel adaptive randomized discontinuation design. The company presented updated data from the trial in three sessions at the American Society of Clinical Oncology meeting June 3-7 in Chicago.
You may also be interested in...
The same advances in scientific understanding of the molecular basis of cancer that have propelled the rise of targeted oncologics also hold out the tantalizing prospect of expanded chemoprevention in cancer, the American Association for Cancer Research suggests in its Cancer Progress Report 2011.
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.